Berlin, Germany

Wolfgang Kübler

This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Borealis Gmbh. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wolfgang Kübler. Retrieved from https://idiyas.com/inventor/wolfgang-kübler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Wolfgang Kübler: Inventor in Medical Research

Introduction

Wolfgang Kübler is an inventor associated with Berlin, Germany. His patent work concerns the potential medical use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators for conditions other than cystic fibrosis. He is associated with 1 patent.

Latest Patents

Kübler’s patent, “Medical use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators,” describes using a CFTR modulator to prevent or treat diseases involving endothelial or epithelial barrier dysfunction, excluding cystic fibrosis. It also covers pharmaceutical compositions containing a CFTR modulator and kits combining two CFTR modulators. The described treatment method involves administering a CFTR modulator to a subject in need, preferably a mammal.

Career Highlights

The information provided associates Kübler with Borealis GmbH and Robert Preißner. These affiliations offer context for his professional background, although specific roles and dates were not provided.

Collaborations

Kübler’s listed coworkers include Lasti Efrinanda Fuaadi and Birgitt Gutbier. The available information does not specify the nature or timing of their collaborations.

Conclusion

Wolfgang Kübler’s listed patent focuses on exploring CFTR modulators as a potential approach to diseases involving endothelial or epithelial barrier dysfunction, extending their proposed use beyond cystic fibrosis.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…